Successes and Challenges of PARP Inhibitors in Cancer Therapy
Author:
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference43 articles.
1. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs;Gibson;Nat Rev Mol Cell Biol,2012
2. Poly(ADP-ribose): novel functions for an old molecule;Schreiber;Nat Rev Mol Cell Biol,2006
3. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase;Bryant;Nature,2005
4. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature,2005
5. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy;Kim;Clin Cancer Res,2015
Cited by 64 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?;Expert Opinion on Investigational Drugs;2024-08-20
2. Second primary malignancies: A clinicopathological study from a tertiary care centre;Journal of Clinical and Scientific Research;2024-01
3. Multiple Primary Malignant Tumours;Journal of Analytical Oncology;2023-12-11
4. Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization;Frontiers in Oncology;2023-12-04
5. Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis;World Journal of Oncology;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3